A panel of experts on renal cell carcinoma discuss patient cases and provide clinical insights on clinical trial data, treatment decisions, and the evolving therapeutic landscape.
EP. 1: Renal Cell Carcinoma: Risk Stratification and Evolving Treatment Landscape
A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.
Watch
EP. 2: Case 1: Therapeutic Sequencing for Relapsed/Refractory Metastatic Clear Cell RCC
Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.
Watch
EP. 3: RCC: Treatment Goals in the Third-Line Setting
Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.
Watch
EP. 4: TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.
Watch